Necrostatin 2 (S enantiomer)

Necrostatin 2 S enantiomer is the S enantiomer of Necrostatin 2. Necrostatin 2 is a potent necroptosis inhibitor, acts as a RIPK1 inhibitor lacking the IDO-targeting effect. Target: RIPK1 [4] Necrostatin 2 is a potent in vitro necroptosis inhibitors (exemplified by 1, EC50-0.05 uM) that also were efficacious in an animal model of ischemic stroke. Many Necroptosis inhibitor derivatives are designed for researchers. Necroptosis is a regulated caspase-independent cell death mechanism that results in morphological features resembling necrosis. It can be induced in a FADD-deficient variant of human Jurkat T cells treated with TNF-a. 5- (1H-Indol-3-ylmethyl) -2-thiohydantoins and 5- (1H-indol-3-ylmethyl) hydantoins were found to be potent necroptosis inhibitors (called necrostatins) .

Product Specifications

CAS Number

[852391-20-9]

UNSPSC

12352005

Target

RIP kinase

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/necrostatin-2-s-enantiomer.html

Purity

99.65

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N(C)C([C@H](CC2=CNC3=C2C=CC=C3Cl)N1)=O

Molecular Formula

C13H12ClN3O2

Molecular Weight

277.71

References & Citations

[1]Teng X, Keys H, Jeevanandam A, Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg Med Chem Lett. 2007 Dec 15;17 (24) :6836-40.|[2]Jagtap PG, Degterev A, Choi S, Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem. 2007 Apr 19;50 (8) :1886-95.|[3]Teng X, Degterev A, Jagtap P, Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005 Nov 15;15 (22) :5039-44.|[4]Takahashi N, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012 Nov 29;3:e437.